3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Osteosarcoma
2
Neoplasms
2
Wilms Tumor
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Metastatic Gastric Adenocarcinoma
1
Malignant Ascites
1
Locally Advanced Unresectable Gastric Adenocarcinoma
1
Hepatoblastoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Biliary Tract Neoplasms
1
Advanced Pancreatic Cancer (Part 1)
1
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
irinotecan sucrosofate
×
Clear all
NCT03119064
2022-12-13
329
Brown University
Phase 1/2
Terminated
12 enrolled
13 charts